Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | CTSG | P08311 | 2/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | MMP7 | P09237 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724615 | 0.86 | HTT (0.40) | PRSS1CTSGCTRB1CMA1TSHR | |
| SCHEMBL3232420 | 0.82 | ATM (0.42) | KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL7567010 | 0.82 | ATM (0.42) | KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL8405171 | 0.82 | ATM (0.42) | KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL7570004 | 0.81 | PPARG (0.44) | MAPT | |
| SCHEMBL3735338 | 0.79 | NPSR1 (0.44) | TSHRMAPTKDM4EL3MBTL1HTT | |
| SCHEMBL8545984 | 0.77 | CYP19A1 (0.38) | TSHRNR3C1ALDH1A1CYP19A1 | |
| SCHEMBL6771725 | 0.74 | TSHR (0.58) | PRSS1CTSGCTRB1CMA1TSHR | |
| SCHEMBL14762666 | 0.73 | MAPT (0.44) | TSHRMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL1226980 | 0.72 | CYP19A1 (0.34) | TSHRMAPTHTTGSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2007770-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| EP-2007771-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20090192149-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-2007771-A1 | IMIDAZO COMPOUNDS | Speedel Experimenta AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| EP-2007770-A1 | IMIDAZO COMPOUNDS | Speedel Experimenta AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116101-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116099-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192149-A1 | Imidazo Compounds | CYP19A1, CYP11B2, GPER1 | PRSS1 3384/4885CTSG 3157/4885CTRB1 1209/4885 |
| US-20090192144-A1 | Imidazo Compounds | REN, CYP11B2, CYP11B1 | PRSS1 755/4885CTSG 4468/4885CTRB1 995/4885 |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | REN, CYP11B2, CYP11B1 | PRSS1 854/4885CTSG 4408/4885CTRB1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.